Medannex is an award-winning Scottish biopharmaceutical company committed to unlocking the therapeutic potential of targeting annexin-A1.

Our goal is to create a first-in-class therapy to improve the lives of people impacted by cancers and autoimmune diseases.

Following a recent Series B fundraise, and supported by both the Scottish Investment Bank and Innovate UK, Medannex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our patent-protected immunomodulatory technology.

Medannex has been shortlisted as a finalist for both ‘Investment of the Year’ and ‘Outstanding Skills Development’ at Scotland’s Life Sciences Annual Awards 2020.

 

Medannex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation.

more

Meet the Team

Meet the people delivering the Medannex company vision. more

Latest News

22.06.20Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting
15.06.20Medannex announces Innovate UK grant award for novel cancer therapeutic development
10.03.20Medannex announces new immunomodulatory approach to cancer treatment at Nature conference
16.02.20Medannex shortlisted in two categories at Scotland’s Life Sciences Awards
view all news

“Medannex has identified a novel and promising target for immunotherapy, and I am delighted to offer guidance as the company prepares for its First-in-Human study.”

Dr Stefan Symeonides,
head of Phase I Trials at the CRUK Edinburgh Centre

Collaborations & Affiliations

Medannex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.